DOX Quote, Financials, Valuation and Earnings

Intellinetics has a net margin of 13.62% compared to Amdocs's net margin of -1.26%. Amdocs's return on equity of 13.99% beat Intellinetics's return on equity of -5.34%.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 9.79%. On the other hand Intellinetics has an analysts' consensus of $17.50 which suggests that it could grow by 20.94%. Given that Intellinetics has higher upside potential than Amdocs, analysts believe Intellinetics is more attractive than Amdocs.

Amdocs has a beta of 0.506, which suggesting that the stock is 49.442% less volatile than S&P 500. In comparison Intellinetics has a beta of 0.548, suggesting its less volatile than the S&P 500 by 45.204%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.12%. Intellinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. Intellinetics pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than Intellinetics quarterly revenues of $4.3M. Amdocs's net income of $151.1M is higher than Intellinetics's net income of -$53.7K. Notably, Amdocs's price-to-earnings ratio is 21.47x while Intellinetics's PE ratio is 248.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 2.15x versus 3.47x for Intellinetics. Usually stocks with elevated PS ratios are considered overvalued.

Sabre has a net margin of 13.62% compared to Amdocs's net margin of -10.45%. Amdocs's return on equity of 13.99% beat Sabre's return on equity of --.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 9.79%. On the other hand Sabre has an analysts' consensus of $4.63 which suggests that it could grow by 82.81%. Given that Sabre has higher upside potential than Amdocs, analysts believe Sabre is more attractive than Amdocs.

Amdocs has a beta of 0.506, which suggesting that the stock is 49.442% less volatile than S&P 500. In comparison Sabre has a beta of 1.330, suggesting its more volatile than the S&P 500 by 32.971%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.12%. Sabre offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. Sabre pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than Sabre quarterly revenues of $714.7M. Amdocs's net income of $151.1M is higher than Sabre's net income of -$74.7M. Notably, Amdocs's price-to-earnings ratio is 21.47x while Sabre's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 2.15x versus 0.32x for Sabre. Usually stocks with elevated PS ratios are considered overvalued.

Signing Day Sports has a net margin of 13.62% compared to Amdocs's net margin of -2893.73%. Amdocs's return on equity of 13.99% beat Signing Day Sports's return on equity of --.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 9.79%. On the other hand Signing Day Sports has an analysts' consensus of -- which suggests that it could fall by --. Given that Amdocs has higher upside potential than Signing Day Sports, analysts believe Amdocs is more attractive than Signing Day Sports.

Amdocs has a beta of 0.506, which suggesting that the stock is 49.442% less volatile than S&P 500. In comparison Signing Day Sports has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.12%. Signing Day Sports offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. Signing Day Sports pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than Signing Day Sports quarterly revenues of $55.4K. Amdocs's net income of $151.1M is higher than Signing Day Sports's net income of -$1.6M. Notably, Amdocs's price-to-earnings ratio is 21.47x while Signing Day Sports's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 2.15x versus 0.49x for Signing Day Sports. Usually stocks with elevated PS ratios are considered overvalued.

WidePoint has a net margin of 13.62% compared to Amdocs's net margin of -1.23%. Amdocs's return on equity of 13.99% beat WidePoint's return on equity of -20.12%.

Amdocs has a consensus price target of $101.61, signalling upside risk potential of 9.79%. On the other hand WidePoint has an analysts' consensus of $6.50 which suggests that it could grow by 29.48%. Given that WidePoint has higher upside potential than Amdocs, analysts believe WidePoint is more attractive than Amdocs.

Amdocs has a beta of 0.506, which suggesting that the stock is 49.442% less volatile than S&P 500. In comparison WidePoint has a beta of 1.805, suggesting its more volatile than the S&P 500 by 80.475%.

Amdocs has a quarterly dividend of $0.53 per share corresponding to a yield of 2.12%. WidePoint offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amdocs pays 42.98% of its earnings as a dividend. WidePoint pays out -- of its earnings as a dividend. Amdocs's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Amdocs quarterly revenues are $1.1B, which are larger than WidePoint quarterly revenues of $34.6M. Amdocs's net income of $151.1M is higher than WidePoint's net income of -$425.2K. Notably, Amdocs's price-to-earnings ratio is 21.47x while WidePoint's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amdocs is 2.15x versus 0.33x for WidePoint. Usually stocks with elevated PS ratios are considered overvalued.